ClinicalTrials.gg
RecruitingNCT06197308Updated May 20, 2026

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

An Early Phase 1 interventional study of oral vancomycin and oral amoxicillin in Primary Sclerosing Cholangitis, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by University of Minnesota · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing vancomycin in Cholangitis, Sclerosing — 6 open to participants now, 6 under way, none of them phase 3. Vancomycin · Cholangitis, Sclerosing.

Planned enrollment
9th of 13
28 · median 32
Started
2024
the only one that year
Phase 1
6 of 13
3 open now
Registered
10th of 13
by date
Lead sponsor
2 of 13
University of Minnesota

Among the 13 studies testing vancomycin in Cholangitis, Sclerosing, this one is the 9th largest by planned enrollment, is the only one that started in 2024, is one of 6 in phase 1, and was the 10th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

6 of the 13 studies testing vancomycin in Cholangitis, Sclerosing are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About vancomycin

Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing vancomycin in Cholangitis, Sclerosing, or all of them as a file.
02

Study summary

This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.

03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-76
  • Serum total at screening ≤ 2x the
  • Absence of biliary obstruction and by ultrasound or equivalent imaging within 6 months of study entry
  • Anticipated maintenance of current medication regimen through the treatment period (UDCA, azathioprine, , methotrexate, 5-ASA, biologic therapy and/or probiotic)
  • 3-month of obeticholic acid or other experimental therapies for PSC
  • Stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and/or video visits or correspondence.

Exclusion criteria

Exclusion Criteria:

  • Antibiotic therapy (except vancomycin) within 3 months or anticipated antibiotic use in the course of the MTT treatment
  • Presence of complications of advanced PSC, such as hepatic encephalopathy, ascites, history of esophageal varices, portal hypertension, hepato-renal syndrome, portopulmonary syndrome, and hepato-pulmonary syndrome
  • Evidence for viral hepatitis (history of is eligible with undetectable HCV RNA); /AIDS
  • Metabolic or inherited liver disease (e.g., Wilson's, hemochromatosis, alpha-1-antitrypsin deficiency)
  • Another disease involving bile ducts (e.g., primary biliary cholangitis, IgG4-related cholangitis, secondary sclerosing cholangitis)
  • Evidence of cirrhosis on the last magnetic resonance cholangiopancreatography (within 6 months)
  • Pregnancy or attempting to become pregnant or breastfeeding.
  • History of liver transplantation, anticipated need for liver transplantation within 12- months from randomization, or a Model of End Stage Liver Disease (MELD) score of ≥15
  • Active
  • Active alcohol overuse (>4 drinks per day for men, and >2 drinks per day for women)
  • Moderate-to-severe renal impairment with a calculated of \< 45 mL/min
  • Neutropenia (an \< 0.5 x 109 cells/L)
  • History of allergic reaction to vancomycin
  • History of allergic reaction to amoxicillin or other beta-lactam antibiotics
  • Any other conditions or abnormalities that, in the opinion of the investigator, may compromise the safety of the subject or interfere with the subject participating in or completing the study
  • Total colectomy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    PCS patients

    Drug: oral vancomycin and oral amoxicillin

Interventions

  • Drugoral vancomycin and oral amoxicillin

    Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.

06

What researchers measure

Primary outcomes

  1. To evaluate safety of MTT in patients with PSC

    Determine the frequency of serious adverse events and other adverse events

    Time frame: 221 days

  2. To evaluate feasibility of MTT in patients with PSC

    Determine proportion of subjects taking 100% of the MTT per protocol.

    Time frame: 221 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Jan 9, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 1, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06197308
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Mar 1, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Amanda Kabage
Contact
kabage@umn.edu
Elizabeth Aby
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vancomycin · Amoxicillin

Start the discussion